Radiopharmaceutical Theranostics CDMO Industry Expands as Targeted Radioligand Therapies Advance

According to a new report published by OG Analysis, the Radiopharmaceutical Theranostics CDMO Market is gaining momentum as drug developers outsource isotope sourcing, radiolabeling, GMP manufacturing, sterile fill-finish, quality control and radioactive distribution. Growth is supported by precision oncology, expanding radioligand therapy pipelines and the need for specialized, reliable clinical-to-commercial supply networks.

Market Overview

Radiopharmaceutical theranostics contract development and manufacturing organizations (CDMOs) provide specialist services for radioactive diagnostic and therapeutic agents. Their capabilities span radiochemistry development, isotope procurement, process scale-up, GMP drug substance and drug product production, aseptic filling, quality release, regulatory CMC support and decay-sensitive distribution. The sector serves targeted oncology therapies and companion imaging agents, including PSMA- and somatostatin receptor-directed programs. Commercial success depends on secure isotope supply, radiation-safe facilities, rapid batch turnaround, trained personnel and reliable regional logistics. Investment is increasingly directed toward multi-isotope production, automated hot cells, redundant capacity and integrated manufacturing networks.

Key Market Insights

●      North America accounts for an estimated 48% of the global market in 2026, supported by extensive radiopharmaceutical development, nuclear medicine infrastructure and specialized manufacturing investment.

●      Therapeutic radiopharmaceuticals account for an estimated 38% share of application/modality demand, supported by expansion of targeted radioligand therapy pipelines and outsourcing.

●      The United States represents approximately 41% of global theranostics CDMO output, followed by Germany at 10.5% and Belgium at 8.5%, according to OG Analysis estimates.

●      Average CDMO selling price is estimated at approximately USD 1,600 per patient-dose-equivalent output in 2026, reflecting a blended mix of diagnostic and therapeutic manufacturing services.

●      Isotope security, GMP compliance, sterile processing, rapid QC release and decay-sensitive transport are central differentiators as sponsors scale from clinical trials to commercial supply.

Market Dynamics

●      Growing use of radioligand therapy in oncology is increasing demand for specialized outsourced radiopharmaceutical development, production and distribution capacity.

●      Clinical pipelines involving beta- and alpha-emitting isotopes are encouraging investment in adaptable hot-cell infrastructure and multi-isotope handling capability.

●      Sponsors are seeking end-to-end CDMO partners that combine radiolabeling, sterile fill-finish, quality testing, regulatory documentation and shipment coordination.

●      Short radionuclide half-lives make production scheduling, batch-release speed, temperature control and logistics coordination essential to supply reliability.

●      Expanding nuclear medicine networks and localized manufacturing hubs create opportunities to improve geographic access and reduce distribution bottlenecks.

●      GMP validation, radiation protection, sterility assurance and specialist workforce requirements raise entry barriers and favor experienced operators.

●      Market growth faces constraints from isotope availability, high capital requirements, specialized labor shortages and regulatory complexity in radioactive transport.

Browse for More Information

https://www.oganalysis.com/industry-reports/water-solenoid-valve-markethttps://www.oganalysis.com/industry-reports/radiopharmaceutical-theranostics-cdmo-market

Market Segmentation

The market encompasses radiopharmaceutical CDMO services including isotope supply support, radiochemistry and radiolabeling, process development, GMP drug substance manufacturing, sterile drug product fill-finish, quality control and batch release, regulatory CMC support and radioactive logistics. Application areas include diagnostic radiopharmaceuticals, therapeutic radiopharmaceuticals and integrated theranostic programs. Geographic coverage includes North America, Europe, Asia-Pacific, the Middle East and Africa, and South and Central America.

Regional Insights

●      North America leads with an estimated 48% share in 2026, supported by a strong oncology development pipeline, specialized nuclear pharmacy networks, isotope access and investment in commercial manufacturing capacity.

●      Europe accounts for an estimated 27%, supported by established radiochemistry expertise, isotope production, nuclear medicine infrastructure and GMP radiopharmaceutical manufacturing networks.

●      Asia-Pacific holds an estimated 17% share, with expanding oncology investment, nuclear medicine services and efforts to localize isotope supply and manufacturing capabilities.

●      Middle East & Africa and South & Central America each account for approximately 4%, with emerging demand linked to nuclear medicine infrastructure and specialized cancer treatment capacity.

Competitive Landscape

Competition centers on reliable isotope sourcing, manufacturing capacity, radiochemistry expertise, GMP compliance, sterile fill-finish, quality release speed and radioactive distribution. Specialist CDMOs, isotope suppliers and nuclear pharmacy networks compete through capacity expansion, regional manufacturing hubs, partnerships and vertical integration. Providers capable of serving both diagnostic and therapeutic programs across clinical and commercial stages are positioned to capture greater outsourcing demand.

Key providers analyzed in the market include Curium, Cardinal Health, SOFIE, Jubilant Radiopharma, Telix Manufacturing Solutions, Nucleus RadioPharma, NorthStar Medical Radioisotopes and other specialized radiopharmaceutical manufacturing and distribution companies.

Recent Developments

●      April 2026 - Cardinal Health reported expansion of actinium-225 production capacity at its Center for Theranostics Advancement in Indianapolis to support targeted alpha therapy programs.

●      March 2026 - TerraPower Isotopes announced plans for a cGMP actinium-225 manufacturing facility in Philadelphia, aimed at increasing isotope supply for radiopharmaceutical development.

●      February 2026 - Novartis outlined plans for an additional U.S. radioligand therapy manufacturing site in Denton, Texas, reflecting demand for expanded therapy supply infrastructure.

●      March 2025 - Novartis received U.S. FDA approval for earlier use of Pluvicto in eligible PSMA-positive metastatic castration-resistant prostate cancer, broadening the treatment pathway.

●      June 2024 - AstraZeneca completed its acquisition of Fusion Pharmaceuticals, expanding its radioconjugate oncology development capabilities and pipeline.